[
  {
    "ts": null,
    "headline": "Tylenol maker’s stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a ‘major overreaction’",
    "summary": "Canaccord Genuity went on social media to gauge the reaction. Even the MAHA crowd was mixed on this one.",
    "url": "https://finnhub.io/api/news?id=297d08d7cc7376d24684cda5e204de24165fa60d67345f2cc64b98ea65a3cb7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757454353,
      "headline": "Tylenol maker’s stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a ‘major overreaction’",
      "id": 136688667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Canaccord Genuity went on social media to gauge the reaction. Even the MAHA crowd was mixed on this one.",
      "url": "https://finnhub.io/api/news?id=297d08d7cc7376d24684cda5e204de24165fa60d67345f2cc64b98ea65a3cb7f"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for Johnson & Johnson, SAP & Coca-Cola",
    "summary": "Zacks Research Daily spotlights Johnson & Johnson, SAP, and Coca-Cola three global leaders navigating growth opportunities and near-term headwinds.",
    "url": "https://finnhub.io/api/news?id=840576d5f5027df62cecd3db12fb2bd7dc65c825832749b529efeaa9ae6a386c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757454060,
      "headline": "Top Stock Reports for Johnson & Johnson, SAP & Coca-Cola",
      "id": 136688668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks Research Daily spotlights Johnson & Johnson, SAP, and Coca-Cola three global leaders navigating growth opportunities and near-term headwinds.",
      "url": "https://finnhub.io/api/news?id=840576d5f5027df62cecd3db12fb2bd7dc65c825832749b529efeaa9ae6a386c"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine intravesical system), a new, potentially practice-changing approach for treating patients with certain types of bladder cancer, addressing the need for additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).1 INLEXZO™, previously referred to as TAR-200, is indicated for the treatment of adul",
    "url": "https://finnhub.io/api/news?id=b06ba26137bdadabc093ae76b20899bc54e081e36f3d24d3358027a9bfc9c5e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757452680,
      "headline": "U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated",
      "id": 136688669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine intravesical system), a new, potentially practice-changing approach for treating patients with certain types of bladder cancer, addressing the need for additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).1 INLEXZO™, previously referred to as TAR-200, is indicated for the treatment of adul",
      "url": "https://finnhub.io/api/news?id=b06ba26137bdadabc093ae76b20899bc54e081e36f3d24d3358027a9bfc9c5e4"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update",
    "summary": "See an update on Prem Watsa's latest 13F portfolio moves, find out his top stock picks, global strategy, and key insights for focused, long-term investing.",
    "url": "https://finnhub.io/api/news?id=628bb2894b5e7b55dcceee727c68da960b38694f77e54a37375520f34a37c29b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757451534,
      "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update",
      "id": 136680992,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1264256639/image_1264256639.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "See an update on Prem Watsa's latest 13F portfolio moves, find out his top stock picks, global strategy, and key insights for focused, long-term investing.",
      "url": "https://finnhub.io/api/news?id=628bb2894b5e7b55dcceee727c68da960b38694f77e54a37375520f34a37c29b"
    }
  },
  {
    "ts": null,
    "headline": "Are You Looking for a High-Growth Dividend Stock?",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=32279ceacfa690c88d99f4c46ccc6be63ebc2c1e2570d4a27723039e31834370",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757436303,
      "headline": "Are You Looking for a High-Growth Dividend Stock?",
      "id": 136688670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=32279ceacfa690c88d99f4c46ccc6be63ebc2c1e2570d4a27723039e31834370"
    }
  },
  {
    "ts": null,
    "headline": "LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal",
    "summary": "Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.",
    "url": "https://finnhub.io/api/news?id=65093b8b993df8431d20cce861c53b55126dfd73614337c2192cc05544d3487c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757435640,
      "headline": "LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal",
      "id": 136688671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.",
      "url": "https://finnhub.io/api/news?id=65093b8b993df8431d20cce861c53b55126dfd73614337c2192cc05544d3487c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets FDA Approval for Bladder Cancer Treatment",
    "summary": "Johnson & Johnson Gets FDA Approval for Bladder Cancer Treatment",
    "url": "https://finnhub.io/api/news?id=8ac7caa3dc1938a6fa6035b1b8bcd3731457f3a5a9e67f30752fdacc0a067f9c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757435460,
      "headline": "Johnson & Johnson Gets FDA Approval for Bladder Cancer Treatment",
      "id": 136751492,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson Gets FDA Approval for Bladder Cancer Treatment",
      "url": "https://finnhub.io/api/news?id=8ac7caa3dc1938a6fa6035b1b8bcd3731457f3a5a9e67f30752fdacc0a067f9c"
    }
  },
  {
    "ts": null,
    "headline": "Burq Makes Fast Company’s Seventh Annual List of the Best Workplaces for Innovators in Small and Mighty Companies: Fewer Than 100 Employees",
    "summary": "SAN FRANCISCO, September 09, 2025--Fast Company today announced its seventh annual Best Workplaces for Innovators list, recognizing businesses that foster a culture of innovation across all levels. Judges singled out six companies as winners in the Small and Mighty Companies: Fewer Than 100 Employees category, with Burq earning a spot for its commitment to redefining last-mile delivery and empowering businesses to scale with flexible, technology-driven solutions.",
    "url": "https://finnhub.io/api/news?id=80098f230651f2475413ec9b2e0e93f86477737b97bcb07975a04c65cc0509f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757435280,
      "headline": "Burq Makes Fast Company’s Seventh Annual List of the Best Workplaces for Innovators in Small and Mighty Companies: Fewer Than 100 Employees",
      "id": 136688672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, September 09, 2025--Fast Company today announced its seventh annual Best Workplaces for Innovators list, recognizing businesses that foster a culture of innovation across all levels. Judges singled out six companies as winners in the Small and Mighty Companies: Fewer Than 100 Employees category, with Burq earning a spot for its commitment to redefining last-mile delivery and empowering businesses to scale with flexible, technology-driven solutions.",
      "url": "https://finnhub.io/api/news?id=80098f230651f2475413ec9b2e0e93f86477737b97bcb07975a04c65cc0509f7"
    }
  },
  {
    "ts": null,
    "headline": "Anxiety Disorders and Depression Treatment Market Growth Trends Report 2025-2033 | Pharmacological and Non-Pharmacological Innovations Strengthen Global Mental Health Support and Treatment Options",
    "summary": "The Anxiety Disorders and Depression Treatment Market is poised for significant growth, escalating from USD 20.51 billion in 2024 to USD 34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Innovations in pharmacological treatments, with",
    "url": "https://finnhub.io/api/news?id=b35e65e905565ca7735d8543f14bf4c252432907d9ec754afb8a3ffe9f68c09d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757431440,
      "headline": "Anxiety Disorders and Depression Treatment Market Growth Trends Report 2025-2033 | Pharmacological and Non-Pharmacological Innovations Strengthen Global Mental Health Support and Treatment Options",
      "id": 136688673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Anxiety Disorders and Depression Treatment Market is poised for significant growth, escalating from USD 20.51 billion in 2024 to USD 34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Innovations in pharmacological treatments, with",
      "url": "https://finnhub.io/api/news?id=b35e65e905565ca7735d8543f14bf4c252432907d9ec754afb8a3ffe9f68c09d"
    }
  },
  {
    "ts": null,
    "headline": "North America Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch, Hoya, Johnson & Johnson, STAAR Surgical, Carl Zeiss, Meditec, Novartis, and USIOL",
    "summary": "The North America Intraocular Lens Market is projected to grow from US$ 1.53 billion in 2024 to US$ 2.38 billion by 2033, achieving a CAGR of 5.00% from 2025 to 2033. Market expansion is driven by the aging population, rising cataract cases, diabetes prevalence, and demand for premium lenses. Technological advancements and efforts by governments and NGOs to enhance eye care access further boost growth. The market includes diverse lens types such as monofocal and multifocal, and key players inclu",
    "url": "https://finnhub.io/api/news?id=493f8be337fd2fe55613600ac8fcb0364d4bbf5487371fca89d6a6613ef4bfdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757430300,
      "headline": "North America Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch, Hoya, Johnson & Johnson, STAAR Surgical, Carl Zeiss, Meditec, Novartis, and USIOL",
      "id": 136688674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The North America Intraocular Lens Market is projected to grow from US$ 1.53 billion in 2024 to US$ 2.38 billion by 2033, achieving a CAGR of 5.00% from 2025 to 2033. Market expansion is driven by the aging population, rising cataract cases, diabetes prevalence, and demand for premium lenses. Technological advancements and efforts by governments and NGOs to enhance eye care access further boost growth. The market includes diverse lens types such as monofocal and multifocal, and key players inclu",
      "url": "https://finnhub.io/api/news?id=493f8be337fd2fe55613600ac8fcb0364d4bbf5487371fca89d6a6613ef4bfdc"
    }
  },
  {
    "ts": null,
    "headline": "Arkose Labs Debuts at No. 83 on Fast Company’s Seventh Annual List of the 100 Best Workplaces for Innovators",
    "summary": "SAN MATEO, Calif., September 09, 2025--Fast Company has recognized Arkose Labs, the leading global account security company, on its seventh annual Best Workplaces for Innovators list.",
    "url": "https://finnhub.io/api/news?id=ff05d260e297634ef76dac6aa561f5a360afb090aa6bda6daaa92d05ec7f7994",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757421000,
      "headline": "Arkose Labs Debuts at No. 83 on Fast Company’s Seventh Annual List of the 100 Best Workplaces for Innovators",
      "id": 136688675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "SAN MATEO, Calif., September 09, 2025--Fast Company has recognized Arkose Labs, the leading global account security company, on its seventh annual Best Workplaces for Innovators list.",
      "url": "https://finnhub.io/api/news?id=ff05d260e297634ef76dac6aa561f5a360afb090aa6bda6daaa92d05ec7f7994"
    }
  },
  {
    "ts": null,
    "headline": "USA Vaccine Market Outlook Report 2025-2030 | Focus on Lassa Fever, Ebola, RSV Vaccines, Alongside Genomics-Driven Targeted Therapies, Strengthens Public Health Preparedness and Investment Potential",
    "summary": "The USA vaccine market is valued at USD 30 billion, driven by health initiatives, disease awareness, and tech advancements. Pfizer, Moderna, and Johnson & Johnson lead, benefiting from R&D prowess and distribution. Growth is spurred by government funding and emerging vaccine innovation, despite challenges like hesitancy and supply disruptions.Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The \"USA Vaccine Market outlook to 2030\" report has been added to ResearchAndMarkets.com's offering.The USA vacc",
    "url": "https://finnhub.io/api/news?id=01b26b6d1e3a658e5fc5e6bd543ec22d3ebf9d02471ad137d9b2234ecaf9ab3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757413260,
      "headline": "USA Vaccine Market Outlook Report 2025-2030 | Focus on Lassa Fever, Ebola, RSV Vaccines, Alongside Genomics-Driven Targeted Therapies, Strengthens Public Health Preparedness and Investment Potential",
      "id": 136688676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The USA vaccine market is valued at USD 30 billion, driven by health initiatives, disease awareness, and tech advancements. Pfizer, Moderna, and Johnson & Johnson lead, benefiting from R&D prowess and distribution. Growth is spurred by government funding and emerging vaccine innovation, despite challenges like hesitancy and supply disruptions.Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The \"USA Vaccine Market outlook to 2030\" report has been added to ResearchAndMarkets.com's offering.The USA vacc",
      "url": "https://finnhub.io/api/news?id=01b26b6d1e3a658e5fc5e6bd543ec22d3ebf9d02471ad137d9b2234ecaf9ab3c"
    }
  }
]